Tuesday, November 5, 2013

Sheraton Hotel
Birmingham Ballroom
2101 Richard Arrington Jr. Boulevard North
Birmingham, Alabama

Cancer Imaging in the 21st Century

Cheri L. Canon, M.D.
Eben Rosenthal, M.D.
Kurt R. Zinn, D.V.M., Ph.D.

Event Logistics
Miranda Wesley

Scientific Sessions
Susan Winn


Paula M. Jacobs, Ph.D., National Cancer Institute

Paula Jacobs is Associate Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute, responsible for the Cancer Imaging Program. She came to work at the NCI after 30 years in the pharmaceutical and medical device industries where she was a key developer of ultrasmall superparamagnetic iron oxide drugs as magnetic resonance imaging agents and iron replacement therapeutics. Her efforts for NCI have been focused on lowering the scientific, logistical, and regulatory barriers to investigational use of PET radiopharmaceuticals for therapeutic drug development by facilitating access to IND filings and by research to develop labeled drugs for clinical and preclinical use. Another effort is focused on wide-ranging aspects of standardization and quantitative imaging techniques and a third focus is on genome-imaging correlations. The Cancer Imaging Program has a portfolio of over 300 funded grants in all areas of imaging science.

Dr. Jacobs serves on three NCI Experimental Therapeutics (NExT) committees to review and manage the projects chosen for development. She directs a radiochemistry facility in Frederick that prepares preclinical and early clinical radiopharmaceuticals in support of therapeutic drug development.

Timothy J. McCarthy, Ph.D., Pfizer Worldwide Research and Development

Timothy McCarthy is an Executive Director and Head of Clinical and Translational Imaging at Pfizer Worldwide Research and Development in Cambridge, MA. He is responsible for the application of quantitative, non-invasive imaging techniques to facilitate the prosecution of compounds in the development portfolio, across all therapeutic areas.

Dr. McCarthy is an organic chemist by training and has spent time working in the field of Positron Emission Tomography (PET) both in academia at Washington University and industry at Pharmacia and Pfizer. Outside of Pfizer, he served as President of the Academy of Molecular Imaging (AMI) from 2007-2010 and is a Fellow of the World Molecular Imaging Society.

Jonathan McConathy, M.D., Ph.D., Washington University in St. Louis

Jonathan McConathy is an Assistant Professor of Radiology in the Department of Radiology at Washington University in St. Louis. He is dual boarded in diagnostic radiology and nuclear medicine. His professional activities include research in the Division of Radiological Sciences and clinical work in the Division of Nuclear Medicine. He serves as program director for the Radiology Research Residency Program at the Mallinckrodt Institute of Radiology. His research group focuses on the development, translation and application of PET tracers for oncology and neuroscience. A major goal of his lab is to develop novel non-natural radiohalogenated amino acids to improve the diagnosis and treatment of primary and metastatic brain tumors and other malignancies. He is also actively involved in combining PET imaging with advanced MRI techniques in preclinical and clinical studies.

Thomas D. Wang, M.D., Ph.D., University of Michigan

Thomas Wang is an Associate Professor in the Departments of Medicine and Biomedical Engineering at the University of Michigan. He also serves as the Principal Investigator of the Michigan Barrett's Esophagus Translational Research Network. He is a board certified gastroenterologist with over 25 years of experience in developing novel optical imaging instruments and molecular probes. Dr. Wang has pioneered the development of wide area fluorescence imaging, the dual axes confocal endomicroscope, and clinical use of fluorescent-labeled peptides for early detection of cancer in the digestive tract. In addition, he is experienced at validating novel optical imaging platforms, and applies his broad training to significantly accelerate the bench to bedside process.